Kidney Transplant Rejection Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)
Kidney Transplant Rejection Market is segmented By Treatment (Immunosuppressive Drugs, Antibody-mediated Rejection Therapies), By Rejection Type (Chronic Rejection, Acute Rejection), By Diagnostic Approach (Biomarker-based diagnostics, Genomics-based diagnostics), By Therapeutics (Small Molecule Inhibitors, Biologic Therapies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD billion) for the above-mentioned segments.
Kidney Transplant Rejection Market Size
Market Size in USD
CAGR8.6%
| Study Period | 2024 - 2031 |
| Base Year of Estimation | 2023 |
| CAGR | 8.6% |
| Market Concentration | Medium |
| Major Players | Eledon Pharmaceuticals, Sangamo Therapeutics, AlloVir, CSL Behring, Hansa Biopharma |
please let us know !
Kidney Transplant Rejection Market Analysis
The kidney transplant rejection market is estimated to be valued at USD 1.5 Bn in 2024 and is expected to reach USD 2.68 Bn by 2031, growing at a compound annual growth rate (CAGR) of 8.6% from 2024 to 2031. Factors such as the increasing prevalence of renal diseases, rising geriatric population, and growing awareness about organ transplantation are fueling the demand for effective rejection treatments.